[Prospects for endothelin-related drugs].
Goto
Katsutoshi
K
Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba.
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000077300:Bosentan; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D000072396:Endothelin-Converting Enzymes; D006439:Hemodynamics; D006801:Humans; D008666:Metalloendopeptidases; D063065:Organophosphonates / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000235:genetics / Q000502:physiology; D013449:Sulfonamides / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D063065:Organophosphonates; C110777:PD 069185; D010456:Peptides, Cyclic; D011799:Quinazolines; D017466:Receptors, Endothelin; C419789:SM 19712; D013449:Sulfonamides; D013453:Sulfonylurea Compounds; D013754:Tetracyclines; D013777:Tetrazoles; C089987:CGS 26303; C098285:CGS 26393; C088494:WS 79089B; C088196:TAK 044; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; D000077300:Bosentan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)